• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Merus Labs appoints two new senior executives

Merus Labs appoints two new senior executives

July 5, 2016
CenterWatch Staff

Merus Labs International has announced two key additions to its executive leadership team effective July 1, 2016, Dr. Michael Bumby as chief financial officer and Frank Fokkinga as Vice president, Global Regulatory Affairs, Quality and Compliance.

Bumby, as chief financial officer, succeed Andrew Patient. Patient will remain with Merus Labs for a period of time to ensure a smooth transition. Bumby was most recently the CFO of Acerus Pharmaceuticals. Bumby had a diverse 14 year career at Eli Lilly, including Corporate Finance & Investment Banking at Lilly's global headquarters in Indianapolis, leading international business development activities for early and late stage assets, and regional CFO for Lilly's Czech and Slovak subsidiaries based in Prague.

The company also appointed Fokkinga as vice president, Global Regulatory Affairs, Quality and Compliance. Based in Zurich, Switzerland, Fokkinga has over 30 years of pharmaceutical experience in regulatory affairs, global market research, business development and market access. Fokkinga has a proven history of success with gaining product approval and market access across Europe in a variety of therapeutic categories. Fokkinga previously served as vice president, International Regulatory Affairs at Takeda Pharmaceuticals. He also progressed a variety of leadership roles at Genzyme (now part of Sanofi) and Organon (now part of Merck). 

"The board of directors and I are delighted to welcome Dr. Bumby and Mr. Fokkinga to the Merus Labs executive leadership team," said Barry Fishman, chief executive officer. "Their enthusiasm, entrepreneurial spirit and expertise is expected to accelerate the execution of our growth strategy."

Merus Labs is a specialty pharmaceutical company focused on acquiring established products. The company leverages its expertise and commercial platform in Europe, Canada and select other markets to deliver value.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing